Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
A data monitoring committee unanimously recommended halting the study of V710 after data showed the vaccine was not likely to have any significant benefits. Further, data showed patients treated with the vaccine were at increased risk of multiple organ failure and mortality (though the mortality risk was reportedly not statistically significant), according to the news report.
Read the news report about Merck and Intercell’s V710.
Related Articles on Infections:
El Camino Hospital’s CMO Outlines 3-Pronged Strategy for C. Diff
Consumer Reports: Some Teaching Hospitals Not the Best for Patient Safety
Study: Peripheral Venous Catheter-Related Infections Often Overlooked
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
